title: Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period.
authors.affiliation: Department of Urology, Hyogo College of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ishibashi
authors.forename: S
authors.initials: S
authors.lastname: Miyamoto
authors.forename: M
authors.initials: M
authors.lastname: Nojima
authors.forename: T
authors.initials: T
authors.lastname: Yoshimoto
authors.forename: H
authors.initials: H
authors.lastname: Yabumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Mori
authors.forename: H
authors.initials: H
authors.lastname: Shima
mesh_terms: D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D008775:Methylprednisolone / Q000627:therapeutic use; D011184:Postoperative Period; D012263:Ribonucleosides / Q000627:therapeutic use; D016559:Tacrolimus / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D016559:Tacrolimus; D008775:Methylprednisolone